Albany Molecular Research Inc
AMRI
AMRI was delisted on the 31st of August, 2017.
131 hedge funds and large institutions have $669M invested in Albany Molecular Research Inc in 2015 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 62 increasing their positions, 38 reducing their positions, and 11 closing their positions.
625% more call options, than puts
Call options by funds: $2.79M | Put options by funds: $385K
63% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 38
17% more capital invested
Capital invested by funds: $571M → $669M (+$97.8M)
9% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 11
0% more funds holding
Funds holding: 131 → 131 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
+$35.1M |
| 2 |
PCM
Palisade Capital Management
Fort Lee,
New Jersey
|
+$4.44M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$4.21M |
| 4 |
BM
Bridger Management
New York
|
+$3.06M |
| 5 |
RFC
Russell Frank Company
Seattle,
Washington
|
+$2.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$22.4M |
| 2 |
IGM
Incline Global Management
New York
|
-$4.72M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$4.4M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.13M |
| 5 |
PTC
Philadelphia Trust Company
Philadelphia,
Pennsylvania
|
-$2.33M |
AMRI Hedge Fund Activity: Q2 2015 in Review
131 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Albany Molecular Research Inc (AMRI) for Q2 2015, worth a combined $669M — up 17% from $571M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new AMRI positions and 11 closed out — a net gain of 1 holder — while 62 added to existing stakes and 38 trimmed.
The largest buyer was Visium Asset Management, adding an estimated $35.1M. The largest seller was HealthCor Management, exiting entirely with an estimated $22.4M sold.
- 131 institutional investors held Albany Molecular Research Inc (AMRI) as of Q2 2015, unchanged from Q1 2015.
- Funds reported $669M of Albany Molecular Research Inc stock for Q2 2015, up 17% quarter-over-quarter.
- 12 funds opened new Albany Molecular Research Inc positions in Q2 2015 and 11 closed out, a net change of +1 holder.
- The largest Albany Molecular Research Inc buyer in Q2 2015 was Visium Asset Management, an estimated $35.1M added.
- The largest Albany Molecular Research Inc seller in Q2 2015 was HealthCor Management, an estimated $22.4M sold.
Based on aggregated 13F filings for Q2 2015.